In vivo CAR-T programs

About Interius BioTherapeutics

Interius BioTherapeutics is a private, pre-clinical-stage biotech developing a novel platform for in vivo genetic medicine delivery. Its core innovation is a programmable lentiviral vector system that can be administered intravenously to genetically modify a patient's own cells inside the body, eliminating the need for complex ex vivo cell manufacturing and pre-conditioning chemotherapy. The company, now part of Kite Pharma (a Gilead company), is advancing a pipeline of in vivo CAR-T candidates and other genetic medicines with the goal of making these transformative treatments broadly accessible. Interius was founded based on direct clinical experience to address the critical limitations of current cell therapy logistics and patient access.

About GenVivo

GenVivo is a private, pre-revenue biotech founded in 2015 and headquartered in San Diego, CA. The company is pioneering an in vivo CAR-T therapy approach using its proprietary G-Volve platform, a targeted, non-replicating retrovector system. Led by a seasoned management team with deep biotech and pharmaceutical experience, GenVivo is advancing a pipeline of novel immunotherapies and operates a fully integrated in-house process development and cGMP manufacturing facility. Its mission is driven by a personal commitment to addressing hard-to-treat cancers with more accessible and effective treatments.

Therapeutic Areas

Other Oncology (unspecified cancers) Drugs